Continuous subcutaneous insulin infusion (CSII insulin pump therapy) for type 1 diabetes: A Bournemouth perspective

Practical Diabetes International

Volumn 25, Issue 3, 2008, Pages 114-117

  Kerr, David ^a,b   Nicholls, Helen ^a,b   James, Janet ^a,b  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b BOURNEMOUTH UNIVERSITY   (United Kingdom)

Author keywords

Future technologies; Insulin pump therapy; Patient selection; Training

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DISEASE SEVERITY; EDUCATION PROGRAM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; PATIENT EDUCATION; QUALITY OF LIFE; RISK ASSESSMENT; SENSOR; WELLBEING;

EID: 54849413034     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1224     Document Type: Article

References (18)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-treated diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361-376.
3. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomised control trials. BMJ 2002; 324: 705-708.
4. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
5. Rodrigues I, Reid H, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion therapy in type 1 diabetes mellitus; a clinical audit in a specialist service. Diabetic Med 2005; 22: 842-849.
6. Chantelau E, Spraul M, Muhlhauser I, et al. Long term safety, efficacy and side-effects of continuous subcutaneous insulin infusion for type 1 diabetes mellitus: a one centre experience. Diabetologia 1989; 32: 421-426.
7. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-751.
8. Gimenez M, Conget I, Jansa M, et al. Efficacy of continuous subcutaneous insulin infusion in type 1 diabetes: a 2-year perspective using the established criteria for funding from a National Health Service. Diabetic Med 2007; 24: 1419-1423.
9. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabetic Med 2007; 24: 607-617.
10. Everett J, Kerr D. Measuring the impact of type 1 diabetes from the patient's perspective. J Diabetes Nursing 2005; 9: 186-190.
11. Kerr D, Everett J. Continuous subcutaneous insulin infusion (CSII), a UK perspective. Infusystems Int 2002; 1: 2-3.
12. National Institute for Clinical Excellence. Guidance on the use of continuous subcutaneous insulin infusion for diabetes. Technology Appraisal Guidance No. 57. National Institute for Clinical Excellence: Feb 2003.
13. National Institute for Clinical Excellence. Diabetes (types 1 and 2) patient education models. Technology Appraisal Guidance No. 60. National Institute for Clinical Excellence, May 2003.
14. Shaban C, Fosbury J, Kerr D, et al. The prevalence of depression and anxiety in adults with type 1 diabetes. Diabetic Med 2006; 23: 1381-1384.
15. Deiss D, Bolinder J, Riveline J, et al. Improved glycaemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730-2732.
16. Jakisch BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multi-centre matched-pair cohort analysis over 3 years. Diabetic Med 2008; 25: 80-85.
17. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-451.
18. Insulin pump services: Report of the Insulin Pumps Working Group. London: Department of Health, March 2007. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_072777